Guidance
← 실적 발표
01
02
03
04 05 06
톤
AI
자본지출
A1 A2
TMO
FY2025 Q4
개선
Thermo Fisher Scientific Inc 실적 발표
Buzzberg 분석
2026 guidance assumes 3-4% organic growth and 6-8% EPS growth
Thermo Fisher reported a strong Q4 2025 with 7% revenue growth and 8% EPS growth, beating its own guidance. Management guided 2026 to 4-6% reported revenue growth and 6-8% EPS growth, assuming stable end markets and continued share gains. Key cross-company signals included a Bayer companion diagnostic win, partnerships with OpenAI and NVIDIA, and acquisitions from Solventum and Sanofi, while highlighting tight sterile fill-finish capacity and strong bioproduction demand. Q4 revenue $12.21B (+7% YoY), adjusted EPS $6.57 (+8%), both ahead of guidance.
Buzzberg 분석 2026 guidance assumes 3-4% organic growth and 6-8% EPS growth Thermo Fisher reported a strong Q4 2025 with 7% revenue growth and 8% EPS growth, beating its own guidance. Management guided 2026 to 4-6% reported revenue growth and 6-8% EPS growth, assuming stable end markets and continued share gains. Key cross-company signals included a Bayer companion diagnostic win, partnerships with OpenAI and NVIDIA, and acquisitions from Solventum and Sanofi, while highlighting tight sterile fill-finish capacity and strong bioproduction demand. Q4 revenue $12.21B (+7% YoY), adjusted EPS $6.57 (+8%), both ahead of guidance. 전체 분석 보기분석 접기
Thermo Fisher reported a strong Q4 2025 with 7% revenue growth and 8% EPS growth, beating its own guidance. Management guided 2026 to 4-6% reported revenue growth and 6-8% EPS growth, assuming stable end markets and continued share gains. Key cross-company signals included a Bayer companion diagnostic win, partnerships with OpenAI and NVIDIA, and acquisitions from Solventum and Sanofi, while highlighting tight sterile fill-finish capacity and strong bioproduction demand. Q4 revenue $12.21B (+7% YoY), adjusted EPS $6.57 (+8%), both ahead of guidance.
- 2026 guidance: revenue $46.3-47.2B (4-6% reported), adjusted EPS $24.22-24.80 (6-8% growth), organic growth 3-4%.
- Biopharma end-market grew mid-single digits full-year; bioproduction and clinical research drove results.
- Bayer companion diagnostic approval and collaborations with OpenAI, NVIDIA highlight innovation partnerships.
매출$12.215B+10% 전분기 대비
주당순이익(EPS)$6.57+13% 전분기 대비
매출총이익률37.95%보고값
영업이익률18.85%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
M&A
Clario acquisition expected to close mid-2026, accretive to EPS
Demand
Biotech funding improving, but spending lags by six months
핵심 내용 3개 더 보기
Guidance
Q1 2026 organic growth expected a few points below full year
Margins
2025 tariffs and FX headwind over 100 bps to margins
Innovation
R&D investments focused on high-impact innovation
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $12.215B | +10% 전분기 대비 |
| 주당순이익(EPS) | $6.57 | +13% 전분기 대비 |
| 매출총이익률 | 37.95% | 보고값 |
| 영업이익률 | 18.85% | 보고값 |
| 잉여현금흐름 | $2.992B | 보고값 |
| 자본지출 | $0.465B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 주당순이익(EPS) | FY2026 | $24.22–$24.80 | $24.51 | 신규 제시 |
| 잉여현금흐름 | FY2026 | $6.8B–$7.3B | $7.05B | 신규 제시 |
| 매출 | FY2026 | $46.3B–$47.2B | $46.75B | 신규 제시 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management expressed confidence in execution and growth strategy, noted strong customer sentiment and innovation momentum, and reaffirmed guidance.
경영진의 AI 분석
Management is integrating AI into operations and products, with a strategic collaboration with OpenAI to embed AI capabilities and improve productivity, and an NVIDIA collaboration for analytical instruments.
투자 및 생산능력
Net capital expenditures are expected to increase to $1.8-2.0 billion in 2026, driven by investments in U.S. manufacturing.
아래에 언급된 기업 7개 모두 표시
기업발표 이후 수익률
고객
고객
Mark Casper
Thermo Fisher's Oncomind DX test was FDA-approved as a companion diagnostic for Bayer's therapy, strengthening Bayer's targeted lung cancer treatment and driving demand for Thermo Fisher's NGS diagnostics.
근거
“this technology received another FDA approval, this time as a companion diagnostic for Bayer's new therapy targeted for certain patients with non-small cell lung cancer.”
파트너
OPENAI
파트너
Mark Casper
Thermo Fisher is partnering with OpenAI to embed AI across its products and operations, potentially accelerating drug development and improving productivity—a positive signal for OpenAI's enterprise adoption in life sciences.
근거
“announced a strategic collaboration with OpenAI aimed at increasing our use of artificial intelligence at the company.”
파트너
Mark Casper
Thermo Fisher's collaboration with NVIDIA leverages AI in analytical instruments and microscopy, positioning NVIDIA's chips in high-end scientific computing applications.
근거
“announced an interesting collaboration with NVIDIA at the beginning of the year.”
공급망
공급망
Mark Casper
Thermo Fisher acquired Solventum's filtration and separation business to extend bioproduction capabilities; Solventum divests a non-core unit for cash.
근거
“completed the acquisition of our filtration and separation business from Solventum.”
공급망
Mark Casper
Thermo Fisher acquires a sterile fill-finish plant from Sanofi, boosting its CDMO capacity; Sanofi monetizes a site while outsourcing fill-finish capacity.
근거
“expanded our U.S. drug product manufacturing footprint through the acquisition of Sanofi's state-of-the-art sterile fill finish site in New Jersey.”
공급망
Mark Casper
Thermo Fisher's bioproduction business delivered 'excellent growth' for another quarter, signaling sustained demand for single-use technologies and cell culture media. — Ongoing bioprocessing demand suggests peer companies in biologics manufacturing supplies (Danaher, Sartorius) may also see tailwinds.
근거
“Performance in the quarter was led by continued strong growth in our bioproduction business”
외부 신호
공급망 알파 · 2발표 이후 수익률
Sterile fill-finish capacity is tight, driving Thermo Fisher to acquire Sanofi's site and win reshoring contracts, indicating supply constraints for drug manufacturers.
근거
“sterile full finish has been the area where there is heightened demand relative to industry capacity”
Thermo Fisher's bioproduction business delivered 'excellent growth' for another quarter, signaling sustained demand for single-use technologies and cell culture media.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 7개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.